Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-04-10
2007-04-10
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S184100, C424S190100, C424S823000
Reexamination Certificate
active
10402466
ABSTRACT:
Recombinant immunogenic compositions and methods for protecting against lethal infections fromBacillus anthracishaving a variant of recombinantBacillus anthracisprotective antigen (rPA) and a variant of recombinantBacillus anthracislethal factor (rLF). These proteins may be expressed separately or as a fusion protein. The recombinant proteins are produced in an avirulent strain ofBacillus anthracisthat overproduces the desired antigens. The compositions and methods induce the animal host to produce antibodies against a virulent strain ofBacillus anthracis.
REFERENCES:
patent: 5591631 (1997-01-01), Leppla et al.
patent: 5677274 (1997-10-01), Leppla et al.
patent: 5840312 (1998-11-01), Mock et al.
patent: 6316006 (2001-11-01), Worsham et al.
patent: 6387665 (2002-05-01), Ivins et al.
patent: 6528063 (2003-03-01), Stram et al.
patent: 6592872 (2003-07-01), Klimpel et al.
patent: 2002/0034512 (2002-03-01), Ivins et al.
patent: 2002/0039588 (2002-04-01), Collier et al.
patent: 2002/0051791 (2002-05-01), Galloway et al.
patent: 2002/0197272 (2002-12-01), Galloway et al.
patent: 2003/0003109 (2003-01-01), Galloway et al.
patent: 97/23236 (1997-07-01), None
patent: 98/11914 (1998-03-01), None
patent: WO 01/21656 (2001-03-01), None
Singh, Y et al, The Journal of Biological Chemistry, vol. 269 (46), Nov. 18, 1994, pp. 29039-29046, The Chymotrypsin-sensitive site, FFD315, in Anthrax toxin Protective antigen is required for translocation of lethal factor.
Arora, N et al, The Journal of Biological Chemistry, vol. 268(5), pp. 3334-3341, Feb. 15, 1993, Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides.
Singh, A et al, FEMS Microbiology Letters, vol. 2098, 2002, pp. 301-305, Expression of anthrax lethal factor gene by osmolyte induction.
Flick-Smith, HC et al, Infection and Immunity, Mar. 2002, pp. 1653-1656, vol. 70(3) A recombinant carboy-terminal domain of the protective antigen ofBacillus anthracisprotects mice against anthrax infection.
Park, S et al, Protein Expression and Purification, vol. 18, pp. 293-302, (20002) Optimized production and purification ofBacillus anthracislethal factor.
Alexeyev, O.A., V. G. Morozov, T. V. Suzdaltseva, A. S. Michukov, and L. A. Steinberg. 1994. Impaired neutrophil function in the cutaneous form of anthrax. Infection 22:281-282.
Brachman, P. S., H. Gold, S. A. Plotkin, F. R. Fekety, M. Werrin, and N. R. Ingraham. 1962. Field evaluation of a human anthrax vaccine. Am.J.Pub.Health 52:632-645.
Bradley, K. A., J. Mogridge, M. Mourez, R. J. Collier, and J. A. Young. 2001. Identification of the cellular receptor for anthrax toxin. Nature 414:160-161.
Bragg, T. S. and D. L. Robertson. 1989. Nucleotide sequence and analysis of the lethal factor gene (lef) fromBacillus anthracis. Gene 81:45-54.
Cieslak, T. J. and E. M. Eitzen. 1999. Clinical and epidemiologic principles of anthrax. Emerg.Infect.Dis. 5:552-555.
Dixon, T. C., M. Meselson, J. Guillemin, and P. C. Hanna. 1999. Medical Progress: Anthrax. N.Engl.J.Med. 341:815-826.
Drum, C. L., S. Z. Yan, J. Bard, Y. Q. Shen, D. Lu, S. Soelaiman, Z. Grabarek, A. Bohm, and W. J. Tang. 2002. Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature Jan. 24, 2002;415(6870):396-402 415:396-402.
Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vande Woude. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor [see comments]. Science 280:734-737.
Flick-Smith, H. C., N. J. Walker, P. Gibson, H. Bullifent, S. Hayward, J. Miller, R. W. Titball, and E. D. williamson. 2002. A recombinant carbosy-terminal domain of the Protective Antigen ofBacillus anthracisprotects mice against anthrax infection. Infect.Immun. 70:1653-1656.
Friedlander, A. M. and P. S. Brachman. 1998. Anthrax, p. 729-739. In S. A. Plotkin and E. A. Mortimer (eds.), Vaccines. W. B. Saunders, Philadelphia.
Friedlander, A. M., P. R. Pittman, and G. W. Parker. 1999. Anthrax vaccine—Evidence for safety and efficacy against inhalational anthrax. Jama-Journal Of The American Medical Association 282:2104-2106.
Gladstone, G. P. 1946. Immunity to anthrax. Protective antigen present in cell-free culture filtrates. Brit.J.exp.Path. 27:349-418.
Green, B. D., L. Battisti, T. M. Koehler, C. B. Thome, and B. E. Ivins. 1985. Demonstration of a capsule plasmid inBacillus anthracis. Infect.Immun. 49:291-297.
Hammond, S. E. and P. C. Hanna. 1998. Lethal factor active-site mutations affect catalytic activity in vitro. Infect.Immun. 66:2374-2378.
Hanna, P. C., B. A. Kruskal, R. A. Ezekowitz, B. R. Bloom, and R. J. Collier. 1994. Role of macrophage oxidative burst in the action of anthrax lethal toxin. Mol.Med. 1:7-18.
Ivins, B., P. Fellows, L. Pitt, J. Estep, J. Farchaus, A. Friedlander, and P. Gibbs. 1995. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosolBacillus anthracisspore challenge in guinea pigs. Vaccine 13:1779-1784.
Ivins, B. E., J. W. Ezzell, Jr., J. Jemski, K. W. Hedlund, J. D. Ristroph, and S. H. Leppla. 1986. Immunization studies with attenuated strains ofBacillus anthracis. Infect.Immun. 52:454-458.
Ivins, B. E. and S. L. Welkos. 1986. Cloning and expression of theBacillus anthracisprotective antigen gene inBacillus subtilis. Infect.Immun. 54:537-542.
Ivins, B. E. and S. L. Welkos. 1988. Recent advances in the development of an improved human anthrax vaccine. Eur.J.Epidemiol. 4:12-19.
Johnson-Winegar, A. 1984. Comparison of enzyme-linked immunosorbent and indirect hemagglutination assays for determining anthrax antibodies. J.Clin.Microbiol. 20:357-361.
Klimpel, K. R., N. Arora, and S. H. Leppla. 1994. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol.Microbiol. 13:1093-1100.
Leppla, S. H. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc.Natl.Acad.Sci.U.S.A. 79:3162-3166.
Leppla, S. H. 2000. Anthrax Toxin, p. 445-472. In K. Aktories and I. Just (eds.), Bacterial Protein Toxins. Springer, Berlin.
Liddington, R., A. Pannifer, P. Hanna, S. Leppla, and R. J. Collier. 1999. Crystallographic studies of the anthrax lethal toxin. J.Appl.Microbiol. 87:282.
Little, S. F. and G. B. Knudson. 1986. Comparative efficacy ofBacillus anthracislive spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect.Immun. 52:509-512.
Little, S. F., S. H. Leppla, and A. M. Friedlander. 1990. Production and characterization of monoclonal antibodies against the lethal factor component ofBacillus anthracislethal toxin. Infect.Immun. 58:1606-1613.
Makino, S., I. Uchida, N. Terakado, C. Sasakawa, and M. Yoshikawa. 1989. Molecular characterization and protein analysis of the cap region, which is essential for encapsulation inBacillus anthracis. J.Bacterial. 171:722-730.
Meselson, M., J. Guillemin, M. Hugh-Jones, A. Langmuir, I. Popova, A. Shelokov, and O. Yampolskaya. 1994. The Sverdlovsk anthrax outbreak of 1979. Science 266:1202-1208.
Mikesell, P., B. E. Ivins, J. D. Ristroph, and T. M. Dreier. 1983. Evidence for plasmid-mediated toxin production inBacillus anthracis. Infect.Immun. 39:371-376.
O'Brien, J., A. Friedlander, T. Dreier, J. Ezzell, and S. Leppla. 1985. Effects of anthrax toxin components on human neutrophils. Infect.Immun. 47:306-310.
Okinaka, R. T., K. Cloud, O. Hampton, A. R. Hoffmaster, K. K. Hill, P. Keim, T. M. Koehler, G. Lamke, S. Kumano, J. Mahillon, D. Manter, Y. Martinez, D. Ricke, R. Svensson, and P. J. Jackson. 1999. Sequence and organization of pXO1, the largeBacillus anthracisplasmid harboring the anthrax toxin genes. J.Bacteriol. 181:6509-6515.
Pannifer, A. D., T. Y. Wong, R. Schwarzenbacher, M. Renatus, C. Petosa, J. Blenkowska, D. B. Lacy, R. J. Collier, S. Park, S. H. Leppla, P. Hanna, and R. C. Liddington. 2001. Crystal structure of the anthrax lethal factor. Nature 414:229-233.
Park, S. and S. H. Leppla. 20
Giri Lallan
Park Sukjoon
Emergent BioDefense Operation Lansing Inc.
Finnegan Henderson Farabow Garrett & Dunner LLP
Portner Ginny Allen
LandOfFree
Recombinant immunogenic compositions and methods for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant immunogenic compositions and methods for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant immunogenic compositions and methods for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3725493